News Update
Widely hailed as the future of phase II drug development, the adaptive I-SPY2 platform trial has set a new benchmark for efficiency, through innovation in trial design and clinical operations.
The Clinical Benefit Index: A Pilot Study Integrating Treatment Efficacy and Quality of Life in Oncology Clinical Trials (P2-12-06)
Basu A, Philip EJ, Dewitt B, et al.
Poster Session 2 -- Hall 1
Site of recurrence after neoadjuvant therapy: clues to biology and impact on endpoints (P2-20-02)
Yau C, Symmans W, Pusztai L, et al.
Poster Session 2 -- Hall 1
Prognostic contribution of predicted sensitivity to endocrine therapy (SET) prior to neoadjuvant chemotherapy for stage II-III hormone receptor-positive and HER2- negative (HR+/HER2-) breast cancer (P2-11-04)
Du L, Yau C, Brown-Swigart L, et al.
Poster Session 2 -- Hall 1
The impact of residual ductal carcinoma in situ on breast cancer recurrence in the neoadjuvant I-SPY2 TRIAL (P3-08-16)
Osdoit M, Yau C, Symmans WF, et al.
Poster Session 3 -- Hall 1
Evaluation of patritumab/paclitaxel/trastuzumab over standard paclitaxel/trastuzumab in early stage, high-risk HER2 positive breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL (P3-11-02)
Helsten TL, Lo SS, Yau C, et al.
Poster Session 3 -- Hall 1
Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL (P3-09-02)
Liu MC, Robinson PA, Yau C, et al.
Poster Session 3 -- Hall 1
HER2 signaling, ER, and proliferation biomarkers predict response to multiple HER2-targeted agents/combinations plus standard neoadjuvant therapy in the I-SPY 2 TRIAL (P4-10-02)
Wolf DM, Yau C, Wulfkuhle J, et al.
Poster Session 4 -- Hall 1
Application of Machine Learning to elucidate the biology predicting response in the I‑SPY 2 neoadjuvant breast cancer trial (P4-10-10)
Sayaman RW, Wolf DM, Yau C, et al.
Poster Session 4 -- Hall 1
Lack of background parenchymal enhancement suppression in breast MRI during neoadjuvant chemotherapy may be associated with inferior treatment response in hormone receptor positive breast cancer (PD9-05)
Onishi N, Li W, Newitt DC, et al.
Session PD-9 -- Stars at Night Ballroom 1&2
Breast cancer subtype specific association of pCR with MRI assessed tumor volume progression during NAC in the I-SPY 2 TRIAL (PD9-04)
Li W, Onishi N, Newitt DC, et al.
Session PD-9 -- Stars at Night Ballroom 1&2
Additive benefit of MRI background parenchymal enhancement (BPE) to an MRI tumor volume model for predicting pathologic complete response (pCR) to neoadjuvant treatment in I-SPY2 (PD9-06)
Arasu V, Kim P, Li W, et al.
Session PD-9 -- Stars at Night Ballroom 1&2
Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: a multi-center pooled analysis (GS5-01)
Yau C, van der Noordaa M, Wei J, et al.
General Session 5 -- Hall 3
Personalized monitoring of circulating tumor DNA during neoadjuvant therapy in highrisk early stage breast cancer reflects response and risk of metastatic recurrence (P5-01-04)
Magbanua MM, Brown-Swigart L, Hirst G, et al.
Poster Session 5 -- Hall 1
Introducing an electronic platform to collect patient reported outcomes in the I-SPY 2 TRIAL, a neoadjuvant clinical trial (OT3-19-02)
Ghersin H, Chattopadhyay A, Blaes A, et al.
Session OT-19 - Trials -- Hall 1
Amsterdam 70-gene profile (MammaPrint) Low Risk, even in the HER2 positive subset, identifies a population of women with lower early risk for recurrence despite low response rates to chemotherapy and to HER2 targeted therapy (P6-10-06)
Pohlmann PR, Yau C, DeMichele A, et al.
Poster Session 6 -- Hall 1
The effect of background parenchymal enhancement on the predictive performance of functional tumor volume measured in MRI (P6-02-01)
Li W, Onishi N, Newitt DC, et al.
Poster Session 6 -- Hall 1
Assessing biomarkers to inform treatment de-escalation: mid-treatment biopsy cellularity predicts pCR in the I-SPY 2 TRIAL (P6-10-02)
Venters SJ, Wolf DM, Brown-Swigart L, et al.
Poster Session 6 -- Hall 1
Karyn DiGiorgio
Quantum Leap Healthcare Collaborative
karyn.digiorgio@quantumleaphealth.org
Sponsored by Quantum Leap Healthcare Collaborative™, a 501C(3) charitable organization accelerating the union of high-impact clinical research and patient care to improve and save lives.
